Abstract :
The number of patients with T2DM is progressively increasing all over the world, and one of the most severe chronic complications of diabetes is the development of Cardiovascular Disease (CVD). The burden of diabetes is now a huge Palestinian public health challenge increase substantially in the next two decades. The aim of the study to investigate the relationship between plasma Galactin-3 and NT-BNP level with the development of CVD in T2DM in Palestinian patients. Case-control study design, this study was conducted in the laboratory of Central laboratory in Remal Clinic, Gaza Strip-Palestine in the period from July to October 2018, included 180 subjects divided to the three groups control, T2DM patients and T2DM with CVD, 60 individual in each group, matching for age. Vacutainer serum and EDTA blood samples were collected from all participants for the laboratory analysis. These results showed that there were highly significant differences (P>0.01) in serum Galectin-3 level in the T2DM group compared with T2DM and CVD group, while NT-BNP results there was no significant difference between the T2DM group and T2DM with CVD group. Also, the study revealed that Galectin-3 was found to be more sensitive and specific by using Roc curve statistical test (sensitivity was 83.3%, specificity was 75.0%, p 0.05) in predicting cardiovascular complications in T2DM patients We concluded that the Galectin-3 is the best novel biomarkers in comparison with NT-BNP that aid in the early diagnostic and prognostic evaluation either alone or in combination with other biomarkers for cardiovascular complications in a patient with T2DM
Keyword :
Galectin-3, NT-BNP, biomarkers, CVD, T2DM, Gaza strip